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Abstract 
Psychiatric nurses face many challenges in providing effective care for patients with schizophrenia who have 
poor insight. The understanding of metacognitive functions in schizophrenia may form a richer idea of why some 
patients deny illness and decline treatment, and may allow for further consideration of effective psychiatric care.  
This study aimed to assess the metacognitive abilities within personal narratives among inpatients with 
schizophrenia and to investigate its relationship with clinical insight and drug compliance. The study followed a 
cross- sectional descriptive correlational research design. It was conducted on 65 male inpatients with 
schizophrenia, at El-Maamoura Hospital for Psychiatric Medicine in Alexandria, Egypt. Indiana Psychiatric 
Illness Interview was used to elicit a narrative of self and illness, the narratives of the study subjects were rated 
using the metacognitive assessment scale concurrently with the assessment of clinical insight and drug 
compliance. The results revealed a statistical significant positive correlation between metacognitive abilities, 
clinical insight and drug compliance. It was concluded that poor insight and drug non-compliance might be 
significantly improved when considering the metacognitive measures.  Recommendations encompassed that 
metacognitive assessment should be integrated in psychiatric care of inpatients with schizophrenia. A form of 
integrative psychotherapeutic intervention that could promote insight and drug compliance through stimulating 
metacognitive abilities should be developed in patients with schizophrenia. Replication of the study is also 
required on more diverse and larger groups of patients. 
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1. Introduction 
Poor insight is a core feature of schizophrenia, it is a complex and controversial phenomenon that is highly 
prevalent, occurring in 57 to 98 percent of patients with schizophrenia (Lehrer& Lorenz 2014). Some patients 
may fluctuate over time in their awareness, being more aware when they are in remission but losing the 
awareness when they relapse (Vidovićet al. 2016). Poor insight can impair a person’s ability to accept the need 
for treatment even with the best of relationships among patients, families, and mental health professionals (Jacob 
2016). It is not only a barrier to treatment adherence, but also a significant contributor to poor functional 
outcomes and prognosis in individuals with schizophrenia spectrum disorders (Novick et al. 2015). 
Poor insight in schizophrenia is prevalent across cultures and phases of illness (Lysaker et al. 2018). A previous 
study reported that up to 80% of all psychotic patients do not take their medication as prescribed  mainly because 
of  poor insight,  which consequently affecting their awareness about  their own needs (Garcíaet al. 2016). By 
examining the relationship between insight and drug adherence over time, Zhou et al (2017) found that poor 
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insight was predictive of medication discontinuation at one‐year follow‐up (Zhou et al. 2017). Also, Czobor et 
al. (2015) postulated that poor insight predicted less adherence at 6 and 12 months follow‐up in drug trials 
conducted in first‐episode psychosis, while Abdel et al (2016) found that insight predicted levels of 
post‐discharge adherence (Czobor et al. 2015 & Abdel Aziz et al. 2016).  
Limited understanding of how poor insight develops acts as a primary barrier for developing methods to address 
insight that are consistent with a recovery-oriented approach (Reddy 2016). As the patient does not perceive the 
symptoms of schizophrenia and cannot distinguish what is real from what is not, making the nurse's role toward 
improving medication compliance a complex task and a constant challenge (Pinho et al.2017).  
Insight is a phenomenon involving not only the acceptance of the facts associated with one’s illness, but also the 
integration of a range of experiences into complex understanding of one’s psychiatric challenges (Arango& 
Amador 2011). It is a dynamic and multidimensional construct situated within the context of a given patient’s 
clinical presentation and cognitive style. It encompasses awareness of illness, relabeling symptoms, and 
recognizing the need for treatment (Czobor et al. 2015).The development of insight requires more than the 
acceptance of fact, it requires the development of a sense of changes in one’s own and other’s internal states that 
have occurred as a result of the onset of mental illness, the selection of pertinent historical events related to the 
illness, and judgments about the causal links between historical events (Arango& Amador 2011). Since then a 
wealth of self report and case studies have confirmed the recalcitrance of these deficits in schizophrenia and 
highlighted their profound impact on the recovery process (Smith et al. 2004).                                                                                                   
The integrated model of insight in schizophrenia has suggested that poor insight may result from multiple factors 
which compromise persons’ abilities to integrate streams of information into a personal awareness of psychiatric 
challenges, and make adaptive responses (Lysaker et al. 2018). This model hypothesized that the origins of poor 
insight in schizophrenia may result, in part, from deficits in metacognitive capacity, or difficulties forming a 
complex and integrated understanding of both one's own thinking as well as the thinking of others regardless of 
clinical profile (Lysaker et al. 2011).  
Metacognition broadly refers to the process of thinking about cognitive states, it can be thought of as a spectrum 
of mental activities ranging from discrete (recognition of thoughts, feelings, and basic judgment) to more 
synthetic capacities (Vohs et al. 2015). Accordingly, poor insight among patients with schizophrenia is related to 
being inaccessible to the knowledge that is plain in the mind of others about changes that have been observed in 
their mental states (Giersch& Mishara 2017). Deficits in the ability to link and synthesize complex ideas about 
oneself and others are the core of disturbances in schizophrenia in which the patients are profoundly unaware of 
their own affects and thoughts as well as the affects and thoughts of others (Dixon et al. 2016).  
Metacognitive deficits might block the ability to perceive and trust the view of others that treatment is needed 
(Lysaker et al. 2018).  These deficits might further limit persons’ abilities to know how their own mental states 
have changed or are changing and to judge the impact of those changes on others (Pinho et al.2017). Moreover, 
they might lead to a lack of complex ideas about painful and confusing events. When these deficits are 
combined, it likely leads to a fragmented view of a life including experiences of mental illness (Lysaker et al. 
2018).                                                      
The narrative research method is especially designed to study the sequence of events that are involved in a 
behavior. It is an appropriate method to study topics where processes, rather than simple single behaviors have to 
be assessed. Meanwhile, an important part of the psychiatric nurses' role in an inpatient setting is interviewing 
patients to assess and manage patients' symptoms (Sobekwa& Arunachallam 2015). By utilizing metacognitive 
interview assessment in clinical setting, the meaningful elements of the human condition in schizophrenia are 
understood (Lysaker et al. 2011). Personal narratives of patients' lives and experiences establish a rational 
mechanism that provides frameworks and schemes of necessary knowledge such as elaboration of the world's 
interpretation, reality, and one's identity framework (Moritz et al. 2018). 
A better understanding of whether different aspects of metacognition are associated with insight and drug 
adherence may help mental health professionals form a richer idea of why some persons with schizophrenia deny 
illness and decline treatment. Therefore, it appears that there would be a clear benefit to investigate 
metacognitive ability in people with schizophrenia. This would be important not only to further develop mental 
health professionals knowledge and understanding of the metacognition capacity in schizophrenia, but also as it 
may contribute towards the development of targeted nursing interventions that could be matched to the pattern of 
metacognitive functioning evident in those with poor insight and drug non compliance. In addition, it could 
allow for further consideration of effective treatment and rehabilitation strategies for these patients. Up to the 
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researchers' knowledge, metacognition has not been investigated among patients with schizophrenia in Egypt, 
and its relationship with clinical insight and medication compliance has not been examined. Hence, the current 
study aimed to assess the metacognitive abilities within personal narratives among inpatients with schizophrenia 
and to investigate its association with clinical insight and drug compliance.   
2. Aims of the Study: 
This study aimed to assess metacognitive abilities within personal narratives of inpatients with schizophrenia and 
to investigate the relationship between metacognitive abilities, clinical insight and drug compliance among 
inpatients with schizophrenia.  
3. Research Question: 
What is the relationship between metacognitive abilities, clinical insight and drug compliance among inpatients 
with schizophrenia?  
4. Methodology 
4.1 Research Design: 
A cross- sectional descriptive correlational research design was utilized in this study.   
4.2 Setting: 
The study was carried out in the inpatient units of El-Maamoura Hospital for Psychiatric Medicine in 
Alexandria. The hospital is affiliated to the Ministry of Health and Population. It serves three governorates 
namely; Alexandria, Matrouh, and El-Beheira. The number of patients with psychotic disorders attending 
inpatient units ranged from 750 to 800 based on official statistics from El- Maamoura hospital in 2016. Patients 
with schizophrenia constitute 350 of the total capacity of inpatients (150 males and 200 females). The services 
provided at the inpatient units include psychiatric examination, diagnosis and dispensing medications.  
4.3 Subjects: 
The subjects of this study included a random sample of 65 inpatients with schizophrenia. The program of Epi 
info 7 was used to estimate the subject size, the minimal sample size was estimated to be 60 patients based on 
the following; the population size was 150 patients, expected frequency 50%, acceptable error 10% and 
confidence co-efficient 95%. 
The subjects of this study met the following inclusion criteria; diagnosed with schizophrenia with no co-
morbidity, able to communicate coherently and relevantly, Male inpatients, and hospitalized for more than one 
week. 
4.4 Data Collection Tools: Five tools were used to collect the study data, these included: 
 Tool I: Bio-sociodemographic and clinical data structured interview schedule: 
This tool was developed to elicit bio-sociodemgraphic data of inpatients with schizophrenia about age, marital 
status, occupation, and level of education. In addition, clinical data as duration of illness, method of hospital 
admission, frequency of hospitalization and duration of current hospitalization.                                          
 Tool II: Compliance Rating Scale (CRS): 
It was adapted from Kemp et al. (1996) and rated based on information from patient's interview and from nurse's 
observation, it has 7 point rating scale ranged from 1 to 7 to quantify the assessment of the level of adherence 
with medication, where 1 indicates “complete refusal” and 7 denotes “active participation”. Patients, whose CRS 
scores above the five cut-off point reflect good adherence, while less than five points indicating insufficient 
adherence (Kemp et al.1996). The Compliance Rating Scale (CRS) was shown to be reliable, Cronbach’s alpha   
coefficient (α) was 0.77 (Kemp et al.1998). 
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 Tool III: The Indiana Psychiatric Illness Interview (IPII): 
The Indiana Psychiatric Illness Interview (IPII) was developed by Lysaker et al. (2002).The IPII is a semi-
structured interview which developed to assess illness narratives. The interview consists of six open-ended 
questions. Firstly, rapport is established and participants are asked to tell their lives' stories as they can. 
Secondly, patients are asked if they think they have a mental illness and how they understand it. Thirdly, a 
question about what has and has not been affected by their condition in terms of interpersonal and psychological 
life. In the fourth question, patients asked about how their condition controls their life and how they control their 
condition. In the fifth question, patients are asked whether their illness was affected by others and how much 
others have been affected by their illness. Finally, the subjects are asked what they expect to stay the same and 
what will be different in the future, in terms of interpersonal and psychological function. The IPII thus results in 
a narrative of self and psychiatric challenges that can be analyzed in terms of metacognition (Lysaker et 
al.2002).    
 Tool IV: Metacognition Assessment Scale (MAS 28): 
It was developed by Semerari et al (2003) to assess metacognitive abilities as manifest in an individual’s 
verbalizations (Semerari et al. 2003). The MAS contains four subscales with 28 items. These subscales include 
“Self reflectivity ” or the ability to think about one’s own mental states (with a range of 0-9); “Understanding of 
Others’ Minds,” or the ability to think about others’ mental states(with a range of 0-8); “Decentration” or seeing 
the world as existing with others having independent motives(with a range of 0-3); and “Mastery” or the ability 
to implement effective strategies in order to cope with problems(with a range of 0-8). Each subscale consists of a 
series of capacities which are arranged in hierarchical order, such that once a capacity is rated (0) as not attained, 
no higher capacities should be possible.                                                                
- Each level of MAS subscales may receive one score to each level attained and 0.5 score can be assigned when 
levels are partially obtained, while   zero score received if the level was unattained. Higher sum values relating to 
a subscale or the total scale indicated higher metacognitive capacities. The obtained scores are summed to 
provide a score for total and each subscale.  
-The studied patients were rated on an a priori basis as having basic self-reflectivity, understanding of others 
mind and mastery capacity if they obtained score“4” or more, where as obtaining less than “4” score reflects not 
having these capacities. A score of “2” or higher on the MAS decentration scale indicates having achieved 
decentration and if they achieved scores of less than “2”indicates not having achieved decentration. For the total 
scale, patients who scored above 14 cut-off point reflect having metacognitive abilities, while less than 14 points 
indicating lack of metacognitive abilities. 
- The MAS and its subscales demonstrated acceptable levels of factorial validity, inter-rater agreement, internal 
validity and test–retest stability. The rating of metacognitive abilities has shown good overall inter-rater 
reliability (ICC = 0.89) and its subscales ranging from 0.83 to 0.89 in patients with schizophrenia (Lysaker et 
al. 2005; Lysaker et al. 2010& Carcione et al. 2008).  
 Tool V: Birchwood Insight Scale (BIS): 
The Birchwood insight scale was developed by Birchwood et al. (1994).The BIS scale consists of 8 items self-
report, to measure the three dimensions of clinical insight (ability to re-label symptoms, awareness of mental 
illness, and recognition of a need for treatment).The first two subscales include two items each, while the third 
subscale includes four items, with all items being statements (e.g., “I am mentally well,” “My doctor is right in 
prescribing medication for me”). It has a three point likert type scale ranged from 0 to 2 where zero indicates 
disagree, one denotes unsure, and 2 reflects agree. The total scores of the items were summed-up; it is ranged 
between 0 to 16. A total score of 9 or more indicates good insight, while scoring less than 9 reflects poor insight. 
For all of these subscales, the higher the score, the greater the level of the measured construct. The BIS scale 
demonstrated high validity and reliability. It has a high internal consistency (Cronbach’s alpha = 0.75) and high 
test-retest reliabilities (0.90). (Compton et al.2011).  
4.5 Method of Data Collection: 
- Written permission was granted from the director of EL-Maamoura Hospital for Psychiatric Medicine in 
Alexandria. 
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- The researchers were trained for applying the study tools under supervision of experts in the field of psychiatric 
nursing. This was done for one month before embarking on the study. 
- Tool I was developed by the researchers. 
-Tools II,III, IV and V were translated into Arabic language. 
-The study tools were tested for content validity by a jury of three experts in the field of psychiatric nursing in 
Alexandria University. 
- Twenty patients were selected randomly to assess the reliability of the study tools. It was found that, the study 
tools were proved to be highly reliable as Cronbach's α been 0.80 for CRS, 0.77 for BIS and 0.88 for total MAS. 
These patients were excluded from the actual study subjects. 
- A pilot study was carried out on 7 patients with schizophrenia, they were chosen randomly from inpatient ward 
to ensure the clarity of the study tools and to identify any obstacles and problems that may hinder data collection. 
Modifications were done accordingly.  
- For the actual study, male wards were ranked by simple randomization by picking their names up from a pool. 
The first selected ward was recruited, then the process was repeated till the required number obtained. 
- All patients' medical charts were reviewed to identify those who met the inclusion criteria 
- Each recruited patient in the study was interviewed individually to establish rapport and explain the aim of the 
study.  
- The patient was encouraged to speak freely, and was given time for reflection and recollection. The interview 
was directed through questions and comments. The interview started with a detailed psychosocial history, which 
creates the departure points for the MAS specific probing. All relevant responses from the patient were examined 
in depth.   
- Metacognitive abilities were assessed through a semi-structured interview using IPII, divided into two sessions 
and typically each session lasted between 45 and 60 minutes. The data were collected during period started from 
November 2016 to February 2017.   
-To assess narratives by using the MAS, two raters have scored each evidence for the display of a given MAS 
capacity which was identified.  
4.6 Ethical considerations: 
- Study procedure was revised and approved by the Ethical Committee of the Faculty of Nursing, Alexandria 
University and by Human Rights Protection Committee of the General Secretariat of Mental Health in Cairo.  
- Informed oral consent was obtained from each patient participated in the study.  
- Data confidentiality was assured.  
- Patient’s privacy and anonymity were maintained and respected.  
4.7 Statistical Analysis: 
Data were fed to the computer and analyzed using IBM SPSS software package version 20.0 (Armonk, NY: IBM 
Corp) Qualitative data were described using number and percent. Quantitative data were described using range 
(minimum and maximum), mean, and standard deviation. Significance of the obtained results was judged at the 
5% level. 
The used tests were:  
1- Student t-test for normally distributed quantitative variables, to compare between two studied groups  
2 - F-test (ANOVA) for normally distributed quantitative variables, to compare between more than two groups 
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3 - Pearson coefficient was to correlate between two normally distributed quantitative variables 
4- The Intra-class Correlation Coefficient (ICC) was to measure of the inter- rater reliability of measurements or 
ratings. 
The followings are guidelines for the interpretation of ICC measures; below 0.50 is poor, between 0.50 and 0.75 
is moderate, between 0.75 and 0.90 is good and above 0.90is excellent. 
5. Results 
Table (I) shows the mean percent scores of clinical insight of inpatients with schizophrenia. The 
displayed table showed that more than two thirds of the studied patients (67.7%) had poor insight. The mean 
scores of re-labeling symptoms, awareness of illness, and need for treatment were 1.83 ± 1.76, 1.32±1.56, and 
2.98±3.06, respectively. Recognizing the need for treatment had the least mean percent score among the studied 
patients (8.27±9.95). 
Table (I): The mean percent scores of clinical insight of inpatients with schizophrenia (n = 65) 
Table (II) reveals the mean scores and inter-rater reliability of metacognitive assessment subscales and 
the total scale. The mean scores of self-reflectivity, understanding of others’ minds, decentration, and mastery 
were 2.42±1.10, 1.86±1.03, 1.01± 0.27 and 1.64±1.20; respectively with the total mean score of 7.12 ± 3.70. 
These reflect that the studied subjects have deficits in metacognitive abilities. As for Inter-rater reliabilities 
(IRRS) , the Intra- Class Coefficient ( ICC) were good for the  self –reflectivity , understanding of others' mind, 
mastery  subscales and the total MAS scales ( ICC=0.84, 0.77, 0.80 and  0.88 respectively ). Whereas, 
decentration subscale has moderate IRRS (ICC=0.71). 
Clinical insight subscales Total score Percent score 
Re-labeling symptoms 
  
Min. – Max. 0.0 – 4.0 0.0 – 100.0 
Mean ± SD. 1.83 ± 1.76 45.77±43.88 
Awareness of illness   
Min. – Max. 0.0 – 4.0 0.0 – 100.0 
Mean ± SD. 1.32±1.56 33.08±39.06 
Need for treatment   
Min. – Max. 0.0 – 8.0 0.0 – 25.0 
Mean ± SD. 2.98±3.06 8.27±9.95 
Overall insight   
Min. – Max. 0.0 – 16.0 0.0 – 100.0 
Mean ± SD. 6.14±5.86 38.37±36.61 
Poor  insight 
No. % 
44 67.7 
Good  insight 21 32.3 
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Table (II) Mean scores and inter-rater reliability of metacognitive assessment subscales and the total scale 
(n = 65). 
Table (III) illustrates the distribution of the studied patients according to the levels of compliance with 
antipsychotic medication. The table revealed that 9.2% have complete drug refusal, 36.9% had partial refusal. 
Those who were very reluctant constituted 10.8%. Nearly one quarter of them (23.1%) have passive acceptance 
and 13.8% have moderate participation. Whereas, none of them (0.0%) has active participation. 
Table (III) Distribution of the studied patients according to the levels of compliance with antipsychotic 
medication (n = 65).                                                                     
Drug compliance scale No. % 
Complete refusal 6 9.2 
Partial refusal 24 36.9 
Very reluctance 7 10.8 
Occasional reluctance 4 6.1 
Passive acceptance 15 23.2 
Moderate acceptance 9 13.8 
Active participation 0 0.0 
Table (IV) shows the correlation between insight and metacognitive abilities of inpatients with schizophrenia (n 
= 65).  It was found strong significant positive correlations between self-reflectivity and relabeling symptoms, 
awareness of illness and the need for treatment (r=0.45, P=0.001, r= 0.596, P= 0.001, and r= 0.36, P= 0.003 
respectively). Also, the overall insight was significantly correlated with self-reflectivity (r=0.52, p=0.001).  
In relation to the understanding of others' mind ability, it was positively and highly correlated with 
relabeling symptoms, awareness of illness and the need for treatment (r=0.28, P= 0.02, r=0.53, P=0.001 and 
r=0.27, P=0.02, respectively). Also, a strong significant correlation was found between understanding of others' 
mind and overall insight (r=0.27, P=0.02). Regarding  the decentration ability, the table showed a high 
significant correlation between decentration and relabeling symptoms, awareness of illness, and the need for 
treatment (r=0.53, P= 0.001, r=0.72, P=0.001, and r=0.55, P= 0.001 respectively). Also, decentration was 
positively and strongly correlated with the overall insight (r=0.68, P=0.001).Speaking of the correlations 
between mastery and clinical insight subscales; relabeling symptoms, awareness of illness, the need for treatment 
and overall insight, the table showed strong and significant correlations (r=0.63, P= 0.001, r=0.59, P=0.001, 
r=0.499, P= 0.001, and r=0.62, P= 0.001, respectively). 
Also, a strong significant correlation was found between the total metacognition score and all dimensions 
of insight (relabeling symptoms, awareness of illness, and need for treatment). (r=0.54, P=0.001, r= 0.68, 
P=0.001, and r=0.47, P=0.001, respectively). It can also be noticed that total metacognition score was positively 
and strongly correlated with overall insight (r= 0.47, P=0.001).  
Metacognitive assessment 
subscales 
Total scores 
Min. – Max. SD ± Mean ICC/ IRR 
Self-reflectivity  0-9 0.50 – 5.0 
2.42±1.10 0.84 
Understanding of others’ minds  0-8 0.50 – 5.0 
1.86±1.03 0.77 
Decentration 
0-3 0.0 – 2.0 1.01± 0.27 0.71 
Mastery 
0-8 1.0 – 4.0 1.64±1.20 0.80 
Total scale 0-28 2.0 – 17.0 7.12 ± 3.70 0.88 
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Table (IV) Correlation between insight and metacognitive abilities of inpatients with schizophrenia (n = 
65). 
MAS        
 Re-labeling 
symptom 
Awareness of 
illness 
Need for 
treatment 
Overall 
insight 
Self-reflectivity 
R 0.450 0.596 0.362 0.522 
P <0.001* <0.001* 0.003* <0.001* 
Understanding of others' mind 
R 0.286 0.531 0.277 0.277 
P  0.021* <0.001* 0.026* 0.001* 
Decentration 
R 0.539 0.724 0.559 0.687 
P <0.001* <0.001* <0.001* <0.001* 
Mastery 
R 0.638 0.592 0.499 0.629 
P <0.001* <0.001* <0.001* <0.001* 
Total MAS 
R 0.547 0.687 0.478 0.478 
P <0.001* <0.001* <0.001* <0.001* 
r: Pearson coefficient  
*: Statistically significant at p ≤ 0.05   
Table (V) reveals the relationship between socio-demographic characteristics, total insight and total rating MAS 
of inpatients with schizophrenia. It was found that the mean score of the total insight and total MAS score 
decreased as the age increased, being 7.53 ± 5.67 and 7.77 ± 4.22, respectively for those who their age ranged 
between 25 to less than 35 years and dropped to 4.67 ± 1.15 and 5.50 ± 1.73, respectively for those who aged 
more than 45years or more. However, no statistical significant difference was found in this respect (F=1.305, 
P=0.281 and F=0.704, P=0.553, respectively).  
In relation to the level of education, the highest mean score of total insight and total rating MAS were 
found among those who had university education (8.38 ± 7.82 and 9.81 ± 5.57 respectively), while those who 
read and write demonstrate the lowest mean score regarding the score of the total insight being 0.0 ± 0.0, and 
5.17 ± 0.29 for the total rating of MAS, with no statistical significant difference was found (F=1.012, P= 0.419 
and F=1.836, P= 0.120). Participants who were divorced have the highest mean score of total insight and MAS 
rating than those who were married and single (10.67 ± 9.24, 11.33 ± 4.62 respectively), with no statistical 
significant difference ( F=1.028, P= 0.364 and F=3.118, P= 0.051). As regard the working status, the table 
revealed that the total insight and total rating MAS were higher in employed patients than those who were 
unemployed (6.31± 6.49, 7.89 ± 4.42 respectively), with no statistical significant difference was found (t= 0.234, 
p= 0.816and t= 1.676, p= 0.100, respectively). Those patients who lived in nuclear family had a tendency to 
demonstrate higher total insight than those who lived with extended family being 6.64 ± 6.14 and decreased to 
5.63 ± 6.68, respectively. While the mean score of the total rating MAS remained nearly the same in both groups 
7.64 ± 3.63 and 7.71 ± 4.29 respectively, with no statistical significant differences (F 0.240, P= 0.868 and F= 
2.270, P= 0.089, respectively). 
Table (V): Relation between socio-demographic characteristics, total insight and total rating MAS 
of inpatients with schizophrenia (n = 65). 
Socio-demographics 
characteristics 
Total insight Total MAS ratings 
Age (years)   
>25 7.25 ± 7.27 6.0 ± 1.87 
25 – 7.53 ± 5.67 7.77 ± 4.22 
35 –  4.64 ± 5.99 6.75 ± 3.40 
≤45 4.67 ± 1.15 5.50 ± 1.73 
F (p) 1.305(0.281) 0.704(0.553) 
Educational level   
Illiterate 7.33 ± 5.68 4.33 ± 1.54 
Read & write 0.0 ± 0.0 5.17 ± 0.29 
Primary 4.86 ± 6.12 6.86 ± 3.34 
Preparatory 6.27 ± 5.89 7.40 ± 2.95 
Secondary 6.15 ± 5.38 7.06 ± 3.68 
University 8.38 ± 7.82 9.81 ± 5.57 
F (p) 1.012(0.419) 1.836(0.120) 
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Marital status   
Single 6.15 ± 5.35 6.45 ± 3.22 
Married 5.50 ± 6.32 7.75 ± 4.07 
Divorced 10.67 ± 9.24 11.33 ± 4.62 
F (p) 1.028(0.364) 3.118(0.051) 
Working status   
Working 6.31 ± 6.49 7.89 ± 4.42 
Not working 5.97 ± 5.26 6.36 ± 2.69 
t (p) 0.234(0.816) 1.676(0.100) 
Living situation   
Alone 6.33 ± 5.22 6.56 ± 2.85 
With extended family 5.63 ± 6.68 7.71 ± 4.29 
With nuclear family 6.64 ± 6.14 7.64 ± 3.63 
Others 4.0 ± 0.0 2.33 ± 0.58 
F (p) 0.240(0.868) 2.270(0.089) 
Table (VI) reveals the relation between clinical data and total insight and total rating MAS of inpatients 
with schizophrenia. Comparing the mean scores of total insight, it appears that the mean score of total insight 
significantly increased among those who had gradual onset of illness compared to those who had sudden onset 
being 7.92 ± 6.05 and dropped to 3.79 ± 4.73 (t= 2.986, P= 0.004). Also, a statistically significant difference 
regarding the mean scores of the total rating MAS was found among those who had gradual onset of illness 
compared to those who had sudden onset being 8.09 ± 3.98 and decreased to 5.82 ± 2.87 (t= 2.675, P= 0.010). 
Inpatients with schizophrenia who are admitted to the psychiatric hospital with voluntary manner scored 
significantly higher mean score on both the total insight and total rating MAS, than those who were hospitalized 
involuntarily (t=5.333, P= 0.001 and t=10.968, P=0.001). 
The results also showed that the mean scores of both the total insight and total rating MAS of inpatients 
with schizophrenia did not show any statistical significant relation with patients' previous psychiatric 
hospitalization, type of treatment and type of drugs (t= 0.048, P= 0.96, t= 1.053, P= 0.29, and F= 0.771, P= 
0.467, F= 0.376, P= 0.688, and F= 0.570, P= 0.568, and F= 0.046, P= 0.955, respectively).  
Table (VI): Relation between clinical data, total insight and total rating MAS of inpatients with 
schizophrenia (n = 65).                                                     
Clinical data Total insight Total rating MAS 
 Previous psychiatric hospitalization   
Yes 6.15 ± 5.80 6.99 ± 3.65 
No 6.0 ± 7.66 9.0 ± 4.56 
 t (p) 0.048(0.962) 1.053(0.296) 
Onset of illness   
Sudden 3.79 ± 4.73 5.82 ± 2.87 
Gradual 7.92 ± 6.05 8.09 ± 3.98 
 t (p) 2.986*(0.004*) 2.675*(0.010*) 
Type of treatment   
Antipsychotic drugs 6.66 ± 5.87 7.45 ± 4.17 
ECT 7.33 ± 5.99 6.42 ± 2.82 
Both antipsychotics and ECT 4.86 ± 5.87 6.71 ± 3.01 
 F (p) 0.771(0.467) 0.376(0.688) 
Type of drugs   
Typical 5.34 ± 5.42 7.19 ± 3.53 
Atypical 5.0 ± 4.24 3.53 ± 4.60 
Mixed 6.88 ± 6.31 7.01 ± 3.91 
 F (p) 0.570(0.568) 0.046(0.955) 
 Mode of admission   
Voluntary 10.38 ± 4.84 11.0 ± 2.71 
Involuntary 3.66 ± 4.93 4.84 ± 1.81 
 t (p) 5.333*(<0.001*) 10.968*(<0.001*) 
Table (VII): shows the relationship between drug compliance, clinical insight and total rating of MAS of 
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inpatients with schizophrenia. It was noted that those who have passive acceptance and moderate participation in 
drug compliance demonstrate highest mean score on both the total insight and total rating MAS (10.40 ± 5.47, 
10.33 ± 3.87 and 11.23 ± 3.07, 10.61 ± 2.09, respectively), with a statistical significant relation was found in this 
respect (F= 7.188, P= 0.001 and F= 317.00, P= 0.001).   
Table (VII): The relationship between Drug compliance and clinical insight and total rating MAS of 
inpatients with schizophrenia (n = 65). 
 
 
 
 
 
 
6. Discussion 
Patients with schizophrenia experience poor insight, and as a result they are at high risk for non-adherence to 
medication which is the most challenging aspect of treating psychotic patients in clinical setting (Higashi et al. 
2013). To understand the cognitive mechanisms of insight in patients with schizophrenia, attention should be 
drawn to the metacognitive abilities in their personal experience of mental illness. The development of insight 
requires an individual not only notices and reflects upon historical events related to one's own illness, but also 
makes sense of such experiences and develops a personally meaningful consensually valid narrative of the illness 
(Reddy 2016). Viewing insight in the light of metacognitive disturbances supports a more individualized 
approach to understanding the psychopathological features of schizophrenia (Lee et al. 2011). It may open a 
door for psychiatric nurses to think about the ways that could enhance patients’ insight and treatment adherence 
in the clinical setting. Hence, the current study aimed at assessing the metacognitive abilities in personal 
narratives, and determining its association with clinical insight and drug compliance among inpatients with 
schizophrenia.  
The results of the present study found that the majority of the studied patients were reluctant or non compliant 
with medication. This result could be attributed to the lack of insight among the studied patients, as shown in the 
present findings, more than two thirds of the studied patients had poor insight, and the need for treatment 
subscale had the least percent mean score. Additionally, there was a statistical significant relation between drug 
compliance and clinical insight among the studied inpatients. Similarly, several studies postulated that drug 
adherence and insight were associated significantly in patients with schizophrenia, those who are not compliant 
with medication did not think they have a mental illness, whereas those who are compliant perceived that they 
have a mental illness (Lee et al. 2011; Vohs et al. 2015& Chan 2016). Also, a meta-analysis study found that 
poor insight was a predictor of poor adherence in 20 of 26 studies reviewed (Paul et al. 2014). 
Recent theories proposed that the metacognitive impairment is a determinant factor of poor insight among 
patients with schizophrenia. Developing insight would need to construct a coherent and integrated account of an 
individual's psychiatric state (Vohs& Lysaker 2014). This was confirmed by the results of the current study 
which revealed that the personal narratives of the studied inpatients with schizophrenia were impoverished in 
metacognitive abilities. The majority of the studied inpatients have a decrement in the total mean score of 
metacognitive abilities and its domains (self reflectivity, understanding of others’ minds, decentration and 
mastery).  The majority of them reported having the awareness that they are producing their own thoughts but 
are not able to identify their emotions and inner experiences. They perceived themselves as unable to control 
what is happening around them. Also, there's a little indication for recognizing others' emotional states and 
distinguishing others' mind operations within their personal narratives. In addition, they are not able to build 
elaborate descriptions of themselves and others, patients reported that they try to stay as healthy as they can, but 
were quite vague about identifying any problems. 
The metacognitive deficits among the studied patients could be attributed to the fact that the neural basis of 
metacognitive efficiency in human prefrontal and parietal cortex regions was found to be highly susceptible to 
Drug compliance  Total insight  Total MAS 
   
Complete refusal 5.67 ± 5.16 3.50 ± 1.84 
Partial refusal 3.29 ± 5.14 4.98 ± 1.83 
Reluctant acceptance 3.36 ± 4.52  5.27 ± 1.57 
Passive acceptance 10.40 ± 5.47 11.23 ± 3.07 
Moderate participation 10.33 ± 3.87 10.61 ± 2.09 
 F (p) 7.188*(<0.001*) 31.007*(<0.001*) 
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atrophy in patients with schizophrenia. Thus may affect the elaboration of linguistic verbal expressions and the 
evaluation strategies as metacognitive tasks in narrative process (Schultz et al. 2010). Moreover, Barra et al. 
(2018) investigated the analysis of the narration evaluative components of interviews of 25 individuals with 
psychiatric diagnosis of chronic schizophrenia and 25 of chronic affective psychosis. They found that there was a 
functional deterioration in the process of elaborating narrative structures especially in the articulation of the 
evaluative component in the patients with chronic schizophrenia while, superficial dysfunctions were manifested 
in the affective psychosis group (Barra et al. 2018).  
Furthermore, the metacognitive deficits could be related to profound neurocognitive impairments in patients with 
schizophrenia which are considered as a constitutive part of the disease, that influence the onset and the 
maintenance of schizophrenia (Lysaker et al. 2014 & Dimaggio et al. 2012).  
Consistent with these findings, Lysaker et al. (2012) found that metacognitive abilities scores of persons with 
first-episode and prolonged schizophrenia have been significantly lower than the scores of samples with 
prolonged non psychiatric medical conditions (Lysaker et al. 2012). Moreover, Vohs et al. (2014) postulated that 
deficits in metacognition have been found in both in earlier and later phases of the schizophrenic illness (Vohs et 
al. 2014). Lysaker et al. (2014) found that patients with schizophrenia have lesser metacognition capacities 
compared with participants with PTSD and substance abuse (Lysaker et al. 2014).  
According to the present findings, clinical insight and drug compliance were significantly related to 
metacognitive abilities among the studied patients with schizophrenia. Those patients with metacognitive deficits 
experienced poor insight and drug non-compliance. This could be attributed to the metacognitive impairment, or 
the disability to form integrated representations of self and others which is a rising potential contributor to poor 
insight among patients with schizophrenia. Similarly, Vohs et al (2014) reported robust correlations between 
metacognitive capacity and multiple domains of clinical insight in first-episode psychosis (Vohs et al. 2014).   
Although the current results revealed that all metacognitive abilities were correlated significantly with clinical 
insight and its dimensions, it has been postulated that patients who had difficulties in reflecting upon themselves 
will be more likely to have difficulty in gaining awareness of their illness, relabeling symptoms and the need for 
treatment (Lysaker et al. 2011). Lyskar et al. (2011) found that self reflectivity was significantly linked with 
awareness of symptoms and mastery with treatment need (Lysaker et al. 2011). Furthermore, an imaging study 
has suggested that insight is related to cortical regions and circuits that may support processes necessary for 
metacognition, including self-consciousness and self-referential processing (Chakraborty& Basu 2010).  
In conclusion, the personal narratives of the studied inpatients with schizophrenia were impoverished in 
metacognitive abilities. The majority of the studied patients were reluctant or non compliant with medication and 
more than two thirds of them had poor insight. The metcognitive deficits among the studied patients were 
significantly associated with poor insight and drug non-compliance. The assessment of the clinical insight and 
drug compliance within the context of metacognitive abilities supports a more individualized approach to the 
understanding of impaired insight and drug non-compliance in patients with schizophrenia. 
According to the results of this study, it can be recommended that metacognitive assessment and therapy should 
be integrated in the clinical settings and in rehabilitation programs for patients with schizophrenia. The 
individualized care plans based on metacognitive assessment should be developed for patients with 
schizophrenia. Techniques to promote patient's self reflectivity and mastery abilities should be incorporated into 
psychiatric care. Stimulating the metacognitive abilities of   patients with schizophrenia through applying a form 
of integrative psychotherapeutic intervention can promote insight and drug compliance. Psychiatric nurses can 
be trained to assess metacognitive abilities and to apply metacognitive therapeutic interventions for inpatients 
with schizophrenia through developing in-service training program for these nurses. Metacognitive functions 
should be integrated in the psychiatric nursing curriculum in nursing schools. 
In addition, further comparative studies will be needed to investigate the differences in metacognitive abilities 
between patients in early and late phases of schizophrenia.  Further studies are also needed to explore when and 
how metacognitive deficits develop. Longitudinal research is needed to understand the complex relationships 
between metacognitive abilities, clinical insight and drug compliance. The feasibility of metacognitive 
interventions should be investigated for different groups with schizophrenia. 
Of note, there are several limitations to this study. It is cross-sectional rather than longitudinal in design. All 
inpatients were male, and generally many years had passed since the onset of their illness. Besides, the majority 
of them were in some form of refusing treatment. Therefore, replication of the study is required on more diverse 
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and larger groups including females, and patients in an earlier phase of illness and those patients with active 
treatment.  
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